An <sup>89</sup>Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor.
Where this comes from
- Record sourced from PubMed, PMID 31420495.
- Also identified by DOI 10.2967/jnumed.119.230466 and PMC identifier 7067531.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an <sup>89</sup>Zr-labeled high-density lipoprotein (<sup>89</sup>Zr-HDL) nanotracer as a means of monitoring response to immunotherapy. <b>Methods:</b> Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. The accumulation of <sup>89</sup>Zr-HDL within the tumor was assessed using PET/CT imaging and autoradiography, whereas TAM burden was determined using immunofluorescence. <b>Results:</b> A significant reduction in <sup>89</sup>Zr-HDL accumulation was observed in PET/CT images, with 2.9% ± 0.3% and 3.7% ± 0.2% injected dose/g for the pexidartinib- and vehicle-treated mice, respectively. This reduction was corroborated <i>ex vivo</i> and correlated with decreased TAM density. <b>Conclusion:</b> These results support the potential use of <sup>89</sup>Zr-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.
Medical subject headings
- Lipoproteins, HDL
- Positron Emission Tomography Computed Tomography
- Radioisotopes
- Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
- Zirconium